We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MPLX:NYSEMPLX LP Analysis

Data as of 2026-04-18 - not real-time

$55.88

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

MPLX is trading close to its short‑term moving averages with a neutral trend and an RSI lingering in the mid‑40s, suggesting limited upward momentum. Technical indicators show a bearish MACD divergence and price sitting just above a well‑defined support level, while volatility over the past month is moderate and beta remains low, indicating limited market‑wide swings. Fundamentally, the company delivers strong operating margins, a solid free‑cash‑flow generation and an attractive dividend yield that sits near eight percent, though the payout ratio is high. Valuation metrics point to a price‑to‑earnings multiple well below the industry average, hinting at relative undervaluation despite a DCF model that appears conservative. Recent analyst upgrades and a consensus “Buy” rating, coupled with upcoming first‑quarter earnings, provide a catalyst for potential price appreciation.
The high dividend yield, stable cash flows and low beta make MPLX appealing for income‑focused investors, while the elevated debt‑to‑equity ratio and reliance on Marathon Petroleum’s asset leases introduce credit considerations. Maintaining a watch on the support zone, dividend sustainability and the Q1 results will be key to confirming the upside narrative.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 6/10

Key Factors

  • Price near technical support with limited downside
  • High dividend yield offering immediate income
  • Neutral market momentum indicated by RSI and MACD

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervalued P/E relative to industry peers
  • Strong operating and free cash flow generation
  • Low beta and stable volume supporting price stability

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Elevated debt‑to‑equity ratio raising credit risk
  • Sustained dividend payout dependent on cash flow
  • Strategic midstream asset base with long‑term demand

Key Metrics & Analysis

Financial Health

Revenue Growth7.10%
Profit Margin41.57%
P/E Ratio11.6
ROE34.71%
ROA7.39%
Debt/Equity180.08
P/B Ratio4.0
Op. Cash Flow$5.9B
Free Cash Flow$2.0B
Industry P/E21.2

Technical Analysis

TrendNeutral
RSI44.1
Support$54.11
Resistance$59.98
MA 20$56.73
MA 50$57.34
MA 200$53.30
MACDBearish
VolumeStable
Fear & Greed Index90.21

Valuation

Fair Value$12.35
Target Price$60.07
Upside/Downside7.50%
GradeUndervalued
TypeValue
Dividend Yield7.71%

Risk Assessment

Beta0.24
Volatility15.49%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.